Product
XmAb23104
2 clinical trials
3 indications
Indication
SarcomaIndication
Metastatic MelanomaIndication
MelanomaClinical trial
Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-04-06
Clinical trial
Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) Combination in Metastatic Melanoma Refractory to Prior Immune Checkpoint Inhibitor Therapy With and Without CNS DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-12-31